Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. WDC
2. DECK
3. RNG
4. BYD
5. WCN
6. SPOT
7. FIX
8. BE
9. BMY
10. NDAQ

Go back to Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)

Seattle Genetics Reports Third Quarter 2019 Financial Results

October 29, 2019 4:02 PM EDT

-Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $167.6 Million in the Third Quarter, an Increase of 32 Percent Over the Third Quarter of 2018-

-Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer Granted Priority Review by FDA; PDUFA Target Action Date March 15, 2020-

-Tucatinib HER2CLIMB Pivotal Trial Met Primary and Both Key Secondary Endpoints; New Drug Application to FDA Planned for the First Quarter of 2020-

-Conference Call Today at 4:30 p.m.... More